Livin/BIRC7 Gene Expression As a Possible Diagnostic Biomarker for Endometrial Hyperplasia and Carcinoma

Overview

Journal J Genet Eng Biotechnol

Specialty Biotechnology

Date 2021 Sep 27

PMID 34568983

Citations 1

Authors

Basma K Elmekkawy

Rasha M S Shoaib

Amal K Seleem

Dalia Shaalan

Entsar A Saad

Affiliations

Soon will be listed here.

Abstract

Background: Livin/BIRC7 is a member of the inhibitors of apoptosis proteins family which are implicated in development of cancer through the inhibition of apoptosis process. This case-control study was intended to investigate livin/BIRC7 gene expression in endometrial hyperplasia and carcinoma and its correlation to some oxidative stress markers in addition to its possible diagnostic performance.

Methods: This study included 90 participants [30 endometrial hyperplasia patients, 30 endometrial carcinoma patients, and 30 healthy controls]. Livin/BIRC7 gene expression was analyzed using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Serum catalase activity was assessed by enzyme-linked immunosorbent assay (ELISA) and malondialdehyde level was measured by the colorimetric method.

Results: Livin/BIRC7 gene expression was significantly (p < 0.001) higher in endometrial carcinoma from patients with endometrial hyperplasia when compared to controls. A positive correlation was found between livin/BIRC7 expression and serum catalase activity and malondialdehyde level in endometrial hyperplasia and carcinoma. The detection of livin/BIRC7 in endometrial carcinoma has excellent sensitivity and specificity.

Conclusions: Livin/BIRC7 was overexpressed in endometrial carcinoma with excellent power to differentiate endometrial carcinoma from endometrial hyperplasia or healthy subjects, suggesting that it might be a useful molecular marker for endometrial carcinoma diagnosis.

Citing Articles

Correction to: Livin/BIRC7 gene expression as a possible diagnostic biomarker for endometrial hyperplasia and carcinoma.

Elmekkawy B, Shoaib R, Seleem A, Shaalan D, Saad E J Genet Eng Biotechnol. 2022; 20(1):27.

PMID: 35147793 PMC: 8837735. DOI: 10.1186/s43141-022-00308-5.

References

Chomczynski P . A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 1993; 15(3):532-4, 536-7. View

Rungruang B, Olawaiye A . Comprehensive surgical staging for endometrial cancer. Rev Obstet Gynecol. 2012; 5(1):28-34. PMC: 3349921. View

Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E . Endometrial cancer. Lancet. 2015; 387(10023):1094-1108. DOI: 10.1016/S0140-6736(15)00130-0. View

Ye L, Song X, Li S, Yang D, Zhang J, Che X . Livin-α promotes cell proliferation by regulating G1-S cell cycle transition in prostate cancer. Prostate. 2010; 71(1):42-51. DOI: 10.1002/pros.21220. View

Sohaib S, Houghton S, Meroni R, Rockall A, Blake P, Reznek R . Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2006; 62(1):28-34. DOI: 10.1016/j.crad.2006.06.015. View

Liu K, Yu Q, Li H, Xie C, Wu Y, Ma D . BIRC7 promotes epithelial-mesenchymal transition and metastasis in papillary thyroid carcinoma through restraining autophagy. Am J Cancer Res. 2020; 10(1):78-94. PMC: 7017743. View

Brown J, Attardi L . The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005; 5(3):231-7. DOI: 10.1038/nrc1560. View

Altieri B, Sbiera S, Della Casa S, Weigand I, Wild V, Steinhauer S . Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget. 2016; 8(6):9323-9338. PMC: 5354734. DOI: 10.18632/oncotarget.14067. View

McCluggage W . My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol. 2006; 59(8):801-12. PMC: 1860448. DOI: 10.1136/jcp.2005.029702. View

10.

Hariu H, Hirohashi Y, Torigoe T, Asanuma H, Hariu M, Tamura Y . Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res. 2005; 11(3):1000-9. View

11.

Braun M, Overbeek-Wager E, Grumbo R . Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2016; 93(6):468-74. View

12.

Byers N, Vandergaast R, Friesen P . Baculovirus Inhibitor-of-Apoptosis Op-IAP3 Blocks Apoptosis by Interaction with and Stabilization of a Host Insect Cellular IAP. J Virol. 2015; 90(1):533-44. PMC: 4702543. DOI: 10.1128/JVI.02320-15. View

13.

Wong R . Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011; 30:87. PMC: 3197541. DOI: 10.1186/1756-9966-30-87. View

14.

Aggarwal V, Tuli H, Varol A, Thakral F, Yerer M, Sak K . Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules. 2019; 9(11). PMC: 6920770. DOI: 10.3390/biom9110735. View

15.

Bruggmann D, Ouassou K, Klingelhofer D, Bohlmann M, Jaque J, Groneberg D . Endometrial cancer: mapping the global landscape of research. J Transl Med. 2020; 18(1):386. PMC: 7552455. DOI: 10.1186/s12967-020-02554-y. View

16.

Li N, Karin M . Is NF-kappaB the sensor of oxidative stress?. FASEB J. 1999; 13(10):1137-43. View

17.

Prat J, Mutch D . Pathology of cancers of the female genital tract including molecular pathology. Int J Gynaecol Obstet. 2018; 143 Suppl 2:93-108. DOI: 10.1002/ijgo.12617. View

18.

Myung D, Park Y, Chung C, Park H, Kim J, Cho S . Expression of Livin in colorectal cancer and its relationship to tumor cell behavior and prognosis. PLoS One. 2013; 8(9):e73262. PMC: 3759411. DOI: 10.1371/journal.pone.0073262. View

19.

Zhuang L, Shen L, Li K, Yang R, Zhang Q, Chen Y . Inhibition of livin expression suppresses cell proliferation and enhances chemosensitivity to cisplatin in human lung adenocarcinoma cells. Mol Med Rep. 2015; 12(1):547-52. DOI: 10.3892/mmr.2015.3372. View

20.

Gu B, Shang X, Yan M, Li X, Wang W, Wang Q . Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecol Oncol. 2021; 161(2):573-580. DOI: 10.1016/j.ygyno.2021.01.036. View